Abstract
This review article presents the pharmacology of combined treatment of Aripiprazole and Escitalopram oxalate in treatment of Major Depressive Disorders. Aripiprazole is anti psychotic agent. Escitalopram Oxalate is also an antidepressant agent (Selective Serotonin Reuptake Inhibitor). Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia. Escitalopram Oxalate is selective serotonin reuptake inhibitors (SSRIs) are a group of chemically diverse antidepressant drugs that specifically inhibit serotonin reuptake. The SSRIs block the reuptake of serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity. The combination of both have decrease dose and improve Depression. Combination of both the drugs were approved by us government and has been used in Major Depressive Disorders. The main objective of this review article is to provide pharmacological information of combined therapy of of Aripiprazole and Escitalopram Oxalate to researcher in development of combined dosage form of this.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call